Searchable abstracts of presentations at key conferences in endocrinology

ea0014oc1.4 | Thyroid clinical | ECE2007

A novel tyrosine-kinases selective inhibitor with anti-tumoral efficacy (Sunitinib) induces a block in iodine uptake and transient hypothyroidism

Mannavola Deborah , Vannucchi Guia , Carletto Marco , Longari Virgilio , Bertuelli Rossella , Coco Paola , Casali Paolo , Beck-Peccoz Paolo , Fugazzola Laura

Sunitinib (SU11248) is a multitarget inhibitor of tyrosine-kinases (RTK) recently tested in clinical trials for the treatment of some human cancers. Side effects are mostly represented by asthenia and appear in a dose and time correlated manner. After the unexpected observation of a myxedematous coma in a patient affected with GIST and treated with Sunitinib, we evaluated the effect of this drug on thyroid function in 24 patients treated for GISTs Imatinib resistant. Patients ...